HC Wainwright & Co. Maintains Buy on Cerevel Therapeutics Hldg, Lowers Price Target to $45
HC Wainwright & Co. analyst Douglas Tsao maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Buy and lowers the price target from $48 to $45.
Why Quoin Pharmaceuticals Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Windtree Therapeutics Inc (NASDAQ: WINT) shares jumped 75.3% to $0.2921. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous Formulation For The Treatment Of Acute Heart Failure."
Earnings Scheduled For February 22, 2023
Companies Reporting Before The Bell
• Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session
Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Data Shows Cerevel’s Emraclidine Does Not Induce High Blood Pressure In Schizophrenia Patients
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) announced results from the Phase 1 trial studying the effect of emraclidine on 24-hour ambulatory blood…
Madrigal Pharmaceuticals, Cerevel Therapeutics And Some Other Big Stocks Moving Higher On Monday
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 90 points on Monday. Here are some big stocks recording gains in today’s session.
Cerevel Reports Results In Emraclidine Ambulatory Blood Pressure Monitoring Trial; Co. Reports ‘Data provide clear evidence that emraclidine does not induce an increase in blood pressure with chronic dosing in people living with schizophrenia’
Data provide clear evidence that emraclidine does not induce an increase in blood pressure with chronic dosing in people living with schizophrenia
Emraclidine demonstrated a mean change from baseline in 24-hour
JP Morgan Maintains Overweight on Cerevel Therapeutics Hldg, Lowers Price Target to $40
JP Morgan analyst Jessica Fye maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Overweight and lowers the price target from $49 to $40.
HC Wainwright & Co. Maintains Buy on Cerevel Therapeutics Hldg, Lowers Price Target to $48
HC Wainwright & Co. analyst Douglas Tsao maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Buy and lowers the price target from $50 to $48.
Why Cerevel Therapeutics Holdings Shares Are Nosediving
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading lower by 6.42% to $25.37 during Tuesday's session after the company reported worse-than-expected third-quarter EPS results and filed for a mixed-securities shelf offering of up to $900 million.